CURRENT PO ITIO

EDUCATION

Fellowship

Residency

Internship

Medical Degree

Col lege

Seong Young Lee 5441 Health Center Drive

Abi lene, Texas 79606 Phone: 325-673-9806

Staff Vitreoretinal Surgeon West Texas Retina Consu ltants, PA 5441 Health Center Drive Abilene, Texas 79606 (2004-present)

Staff Investigator Retina Research Institute of Texas 544 1 Health Center Drive Abi lene, Texas 79606 (2004-present)

Medical Director Abilene Surgery Center 560 I Health Center Drive Abilene, Texas 79606 (2008-present)

Section Chair of Ophthalmology Hendrick Medical Center, 1900 Pine Street Abilene, Texas 7960 I (2005-2006, 20 I 0-prescnt)

University of Texas Southwestern Medica l School at Dallas Dallas, Texas (2002-2004) Retina

Medical College of Georgia Augusta, Georgia ( 1999-2002) Ophthalmology

Baylor College of Medicine Houston. Texas ( 1998-1999) Internal Medicine

University of Texas Southwestern Medical School at Dallas Dallas, Texas ( 1994-1998)

Rice University Houston, Texas ( 1990-1994) B.A. in Biochemistry

HO OR &AWARD

MCG Ophthalmology Resident Research Award, 2001 l lonors in Ophthalmology and Psychiatry Clerkships, 1996-1997 Southwestern Medical Foundation Scholarship for Academic Achievement, 1994-1995 Phi Lambda Upsilon (National Chemical Honor Society), 1994 Rice Class of 1930 cholarship (Tuition merit scholarship), 1993 Rice University President's l lonor Roll, 1990-1994 National Merit Scholarship, 1990-1994 YMCA/King Foundation College Scholarship, 1990-1994 Dallas Morning News/Dallas Mavericks College Scholarship, 1990 National Leadership and Service Award, 1990 Valedictorian, Jesuit College Preparatory School of Da llas, 1990

RESEARCH

Sub-Investigator, Allergan REACH AGN-150998, " ingle and Repeal Dose of the Safety and Efficacy of AGN-150998 in patients with Exudative Age-related Macular Degeneration" Primary Investigator: Sunil S. Patel, M.D., PhD Ju ly 20 It-Present

Sub-Investigator, Lpath NEXUS LTl 009-0ph-003, "A phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSonep TM(Sonepcizumab [L Tl 009]) As either Monotherapy or adjunctive Therapy to Lucent is® or Avastin® Alone for the treatment of subjects with choroidal Neovascularization Secondary to Age-Related Macular Degeneration" Primary Investigator: Sun il S. Patel, M.D., PhD July 2011-Present

Sub-lnvestigator, Allergan BOP 208397-00 I, "A 12-Month , Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the afety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (R YO)" Primary Investigator: Sunil S. Patel, M.D., PhD Apri l 2011-Present

Sub-Investigator, Alimera FAME C-01- 11 -008," An Open Label, Multi-center Extension Study of the Safety and Utility of the New Inserter of lluvien ® (Fiuocinole Acetonide lntravitreal Insert) 0.19mg and the Safety of lluvien in subjects with Diabetic Macular Edema" Primary Investigator: Sunil S. Patel, M.D., PhD March 201 1-Present

ub-Investigator, GlaskoSmithKiine BAM 114341, "A Phase fl, Multi-Centre, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics ofGSK933776 in Adult Patients with Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)" Primary Investigator: Sunil S. Patel, M.D., PhD February 20 It-Present

Sub-Investigator, Lpath Incorporated L Tl 009-0PII002, "A Phase I B Multicenter, Open-Label and Randomized study of ISONEP (Sonepcizumab!L T I 009) administered as Intravenous Injections to subjects with PED Secondary to Exudative f\:ge-Related Macular Degeneration or Polypoidal Choroidal Yasculopathy." Primary Investigator: Sunil S. Patel, M.D., PhD March 2011-Present

Sub-lnvestigator, Genentech Shore FVF4967g, "A Multicenter Randomized tudy Evaluating Dosing Regimens for Treatment with lntravitreal Ranibizumab in Subjects with Macular Edema Following Retinal Vein Occlusion." Primary Investigator: Suni l S. Patel, M.D., PhD February 20 It -Present

Sub-Investigator, Regeneron Vista VGFT-OD-1 009, "A Double-Masked, Randomized, Active-Controlled. Phase Ill tudy of the Efficacy and afety of lntravitreal Administration ofVEGF Trap-Eye in Patients with Diabetic Macular Edema" Primary Investigator: Grant P. Janzen, M.D. February 20 11-Present

Sub-Investigator, Genentech Mahala CFD4870g, "A Phase lb/LI , Multicenter, Randomized, Single Masked, Sham-I njection-Controlled study of Safety, Tolerability, and Evidence of Activity of FCFD4514S lntravitreal Injections Admin istered month ly or Every other month to patients with Geographical Atrophy." Primary Investigator: Sunil S. Patel, M.D., PhD December 2010-Present

Sub-lnvestigator, Allergan 190342-033D, "A Mu lticenter, Patient-Masked, afety Extension Study to Evaluate Ule biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System." Primary Investigator: Sunil S. Patel, M.D., Ph.D. August 2010-Present

Sub-Investigator, DRCR Protocol N, "An Evaluation of lntravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy." Primary Investigator: Sunil S. Patel M.D., Ph.D. July 20 tO-Present

Sub-lnvestigator, Ophthotech OPH I 00 I, ''A PHASE 2, Randomized, Double-Masked, Controlled trial to establish the safety and efficacy of intravitreous injections of E I 0030 (Anti-PDGF Pegylated Aptamer) Given in combination with Lucentis® in subjects with Neovascu lar Age-Related Macular Degeneration" Primary Investigator: Sunil S. Patel M.D., Ph.D. March 20 I 0-Present

Sub-Investigator, Pfizer B 1181002, "A Phase I, Double-masked, Placebo-controlled study eva luating the Safety and Tolerability, lmmunogcnicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G (PF-04382923) in subjects with Advanced Dry, Age-Related Macular Degeneration (AMD) including Geographical Atrophy" Primary Investigator: Sunil S. Patel, M.D., PhD February 20 l 0-Present

Sub-Investigator, Regeneron VGFT-OD-0819, "A Randomized, Double Masked, Controlled Phase Ill Study of the efficacy, safety and tolerability of repeated intravitreal administration of VEGF-Trap in subjects with Macu lar Edema Secondary to Central Retinal Vein Occlusion (CRVO)." Pri mary Investigator: Suni l S. Patel, M.D., Ph.D. August 2009-Present

Sub-Investigator, Genentech FVF4579g Harbor, "A Phase Jll, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the efficacy and safety of O.S mg and 2.0 mg Ranibizumab administered monthly or an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-related Macular Degeneration." Primary Investigator: Sunil S. Patel, M.D., Ph.D. June 2009-Present

Primary Investigator, Alcon C-08-36 (GATE), "The safety and efficacy of AL-83098 ophthalmic Solution for the treatment of Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)." Sub-lnvestigator: Sunil S. Patel, M.D., Ph.D. February 2009-Present

Sub-Investigator, Genentech FVF4168g RIDE," A phase Ill, double-masked, multicenter, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus." Primary Investigator: Sunil S. Patel, M.D., Ph.D. April 2007-Present

Sub-Investigator, Ophthotech OPH3000ss. "A phase I ascending dose and parallel group trial to establish the safety, tolerability, and pharrnacokenetics profile of multiple intravitreous injections ofVolociximab (aSP I intcgrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration." Pri mary Investigator: Sunil S. Patel, M.D., Ph.D. October 20 I 0- December 20 II

Sub-Investigator, Victor Gonza les, M.D.,PRESERVE, "Pegaptanib for Ret inal Edema Secondary to DiabeticVascular Disease." Primary Investigator: Sunil S. Patel, M.D. , Ph.D. June 20 I 0-December 20 II

Sub-Investigator, Allcrgan 190342-0310-0 I, "A Multicenter, Masked, Randomized, Sham Controlled, Parallel-group, 3-month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in improving Visual Function in patients with a previous Rhegmatogenous Macular-Off Retinal Detachment." Primary Investigator: Sunil S. Patel M.D., Ph.D. October 2009-December 20 II

Sub-lnvestigator, DRCR Protocol 0, "Comparison ofTime Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema." Primary Investigator: Sunil S. Patel, M.D., Ph.D. August 2009- October 20 II

Sub-Investigator. Allergan 190342-032D-O I, "A Multicenter, Masked, Randomized, Sham-controlled, Paired-eyed Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal structure and Visual Function ofBrimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DOS) Applicator system in Patients with Geographical Atrophy from Age-Related Macular Degeneration." Primary Investigator: Suni l S. Patel, M.D., Ph.D. June 2008-August 20 I I

Sub-Investigator, Regcneron VGFT-OD-0605, "A randomized, double masked, active controlled Phase Ill study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with Ncovascular Age-Related Macular Degeneration." Primary Investigator: Sunil S. Patel, M.D., Ph.D. July 2007-July20 I I

Sub-Investigator, Alcon C-09-023 (Waltz), "A dose-escalated study of AL-39324 Suspension versus Lucentis® for the treatment of Exudative Age Related Macular Degeneration." Primary Investigator: Sunil S. Patel M.D., Ph.D. November 2009-June 2011

Sub-Investigator, Ophthotech OPH200 I, "A Phase I study to establish the safety and tolerability of ARC 1905 (ANTI-CS APTAMER) in subjects with Dry Age-Related Macular Degeneration." Primary Investigator: Sunil S. Patel, M.D., Ph.D. June 2009-June 20 II

Sub-Investigator, Alimera Sciences CO 1-05-00 I, "A randomized, double-masked, paral lel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-00 I A O.Sj.Lglday and ASI-00 I B 0.2j.Lg/day Fluocinolone Acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema.'' Primary Jnvestigator: Sunil S. Patel, M.D., Ph.D. April 2006-Feb 20 II

Sub-Investigator, Regeneron VGFT-00-0706, "A Double-Masked, Randomized, Controlled study of the safety and efficacy, Tolerabil ity and Biological effect of repeated lntravitreal Administration ofVEGF-Trap in patients with Diabetic Macular Edema (DME)." Primary Investigator: Sunil S. Patel, M.D., Ph.D. February 2009-Jan 20 II

Primary Investigator, Genentcch FVF3426g HORJZON, " An open-label, Multicenter extension study to evaluate the safety and tolerability ofRanibizumab in subjects with Choroidal Neovascularization (CNY) secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have completed a Genentech-sponsored Ranibizumab study." Sub-Investigator: Sunil S. Patel M.D., Ph.D. July 2008- Oct 2010

Sub-Investigator, Allergan 206207-018, "A 26-week, Open-Label study to asses the safety and efficacy of 700f..lg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the treatment ofYitrectomized subjects with Diabetic Macular Edema." Primary Investigator: Sunil S. Patel, M.D., Ph.D. December 2008-July20 I 0

Sub-Investigator, Allergan 206207-019, "A 26-week, Open Label study to asses the safety and efficacy of700f..lg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® in the treatment of subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration." Primary Investigator: Suni l S. Patel, M.D .. Ph.D. December 2008-July 20 I 0

Primary Investigator, Allergan 206207-012-00, "A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700J.lg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema (DME)." Sub-Investigator: Suni l S. Patel, M.D., Ph.D. April 2007-May 20 I 0

Sub-investigator, Ophthotech OPH3000, "A phase I ascending dose and parallel group trial to establish the safety, tolerability, and phannacokenetics profile of multiple intravitreous injections ofVolociximab (aS~ I integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mgleye in subjects with Neovascu lar Age-Related Macular Degeneration.'' Primary Investigator: Sunil S. Patel, M.D., Ph.D. July2008-May 20 I 0

Sub-Investigator, Ophthotech OPH2000, "A Phase I, A cending Dose and Parallel Group Trial to establish the Safety, Tolerabi lity and Pharmacokinetic Profile of Multiple [ntravenous Injections of ARC1905 (ANTI-CS APTAMER) Given either in combination therapy with multiple doses of Lucent is® 0.5 mgleye, or with one induction dose of Lucentis® 0.5 mgleye in subjects with Neovascular Age-Related Macular Degeneration." Primary Investigator: Sunil S. Patel, M.D., Ph.D. June 2008-May 20 I 0

Sub-Investigator, Ophthotech OPHI 000, "A Phase L, single ascending dose trail to establish the safety, tolerability and phannacokinetic profile of intravitreous injection of E I 0030 (Anti-PDGF Pegylated A pta mer) monotherapy and of E I 0030 given in combination with Lucentis 0.5 Mgleye in subjects with Neovascular Age-Related Macular Degeneration.'' Primary Investigator: Sunil S. Patel, M.D., Ph.D. November 2007-May 20 I 0

Primary Investigator, Genentech FVF4166g CRUISE, ''A phase Ill , multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vei n occlusion." Sub-Investigator: Sunil S. Patel, M.D., Ph.D. April 2007-February 20 I 0

Primary Investigator, Genentech FVF4165g BRA YO," A phase 111 multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion." Sub- Investigator: Sunil S. Patel, M.D., Ph .D. Aprii2007-February 20 I 0

Sub- In vestigator, Jerini J064270 I, "A Phase I open-labe l study to investigate the safety, tolerability and pharmacokinetic profi le of single and repeated doses of JSM6427 following administration by intravitreal injection in patients with Ncovascular Age-Related Macular Degeneration." Primary Investigator: Sunil S. Patel, M.D .. Ph.D. September 2007-September 2009

Sub-investigator, ALCON C-06-30, "The Natural IIi story of Geographical Atrophy Progression (GAP) Secondary to Age-Related Macular Degeneration (AMD)." Primary Investigator: Sunil S. Patel, M.D., Ph .D. August 2008-August 2009

Sub-Investigator, OPKO ACU30 I C," A Phase 3, Randomized, Double-masked, Parallel-assignment study of lntravitreal Bevasiranib odium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD)." Primary In vestigator: Sunil S. Patel, M.D., Ph.D. July 2007-Jul 2009

Sub-Investigator, The Standard Care vs. Corticostero id for Retina Vein Occ lusion (SCORE) Study. "Two Randomized Trials to Compare the Efficacy and Safety of lntravitreal Injections of T riamcinolone Acctonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retina l Vein Occlusion." Primary Investigator: Sunil S. Patel. M.D., Ph .D. August 2004-June 2009

Primary lnvestigator, Allergan 206207-016, "A 6-Month, single- masked, multicenter, randomized, contro lled study to assess the safety and efficacy of 700~g Dexamethasone posterior segment drug delivery system applicator system as adjunctive therapy to Lucentis compared with Lucentis alone in the treatment of patients with Choroidal Neovascu larizat ion secondary to Age-Re lated Macular Degeneration." Sub-Investigator: Sunil S. Pate l, M.D., Ph .D. August 2007-May2009

Sub-Investigator, Allergan SIRIUS, "A 2- year, Multicenter, randomized, controlled, masked, dose-finding trial to asses the safety and efficacy of multiple intravitreal injections of AGN 2 1 1745 in patients with subfoveal choroidal neovascularization secondary to age-re lated macular degeneration" Primary Investigator: Sunil S. Patel , M.D., Ph .D. April 2007-May 2009

Primary Investigator, Allergan 206207-009-0 I, "A six-month, phase Ill, multicenter, masked randomized, sham-contro lled trial (with sixOmonth open label extension) to assess the safety and efficacy of700~g and 350~g dexamethasone Posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion." Sub-Investigator: Sunil S. Patel, M.D., Ph.D. February 2006-March 2009

Sub-Investigator, ALCON C0459, "Anecortave Acetate 15mg administered every 3 months versus Anecortave Acetate 15mg administered every 6 months versus Anecortave Acetate 30mg administered every 6 months in patients with exudative age-related macular degeneration." Primary [nvestigator: Sunil S. Patel, M.D., Ph.D. May 2005-November 2008

Sub-Investigator, Eyetech I 023 , "A phase JV, multi-center trial of maintenance intravitreous injections of Macugen®(Pegaptanib Sodium) given every 6 weeks for 48 weeks in subjects with subfovealneovascular age-related macular degeneration (AM D) initially treated with modality resulting in maculopathy improvement." Primary Investigator: Sunil S. Patel, M.D., Ph.D. June 2006-0ctober 2008

Sub-Investigator, Anecortave Acetate Risk-Reduction Trial (AART) C-02-60. "Multicenter, double-masked, randomized, parallel groups clinical trial to demonstrate that Anecortave Acetate is safe and effective versus sham in arresting the progress ion of non-exudative AMD in patients who are at-risk for progressing to exudative AMD." Primary investigator: Sunil S. Patel, M.D., Ph.D. August 2004-0ctober 2008

Sub-Investigator, Diabetic Retinopathy Clinical Research Network. "A Randomized Trial Comparing lntravitreal Corticosteroids and Laser Photocoagulation for Diabetic Macular Edema." Primary Investigator: Sun il S. Patel, M.D .. Ph.D. August 2004-2007

Primary Investigator. Alcon C-05-62, ·'A cl inical evaluation of the safety and efficacy of preservative-free Triamcinolone Acetonide sterile suspension for visualization during vitreoretinal surgery." Sub-Investigator: Sunil S. Patel, M.D., Ph.D. August 2007-0ctober 2007

ub-lnvestigator, DRCR Protocol B, " A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for DME." Primary Investigator: Sunil S. Patel, M.D., Ph.D. September 2004-August 2008

Sub-Investigator, EYETECH EOPIOI3," A phase 2/3, randomized, controlled, double-masked, multi-center, comparative dose-finding trial in parallel groups, to compare the safety and efficacy of intravitreous injections of0.3, 0.03, 0.003mg Macugen, given as often as every 6 weeks for 3 years, to sham injections, in subjects with Diabetic Macular Edema involving the center of the macula." Primary Investigator: Sunil S. Patel, M.D., Ph.D. September 2005-May 2007

Primary Investigator, ALCON C0418 "Clinical evaluation of the safety ofNext Generation Ophthalmic Irrigating Solution Compared to BSS Plus for use During Surgery for removal of epimacular membrane and vitrectomy." Sub-lnvestigator: Sunil S. Patel, M.D., Ph .D. February 2006-March 2007

Sub-lnvestigator, EYETECH EO PI 012, "A pha e 38/4, randomized, activ-controlled, double masked, single du mmy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to I 02 weeks plus sham Photodynamic Therapy to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration." Primary Investigator: Sunil S. Patel, M.D., Ph.D. March 2005-February 2007

Primary Investigator, Genaera Corporation MSI-1 256F-208. "A Phase 2, Multi-center, Randomized, Controlled, Masked Study of the Effects of Squalamine Lactate in Combination with Visudyne in Patients with Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.''

ub-lnvestigator: unit S. Patel, M.D., Ph.D. December 2004-2005

Primary Investigator, Genaera Corporation MSI-1256F-209. '·A Phase 2, multi-center, Randomized, Masked, Controlled Study of the MSI-1256F (Squalamine Lactate) for Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macu lar Degeneration." Sub-Investigator: Suni l S. Patel , M.D., Ph.D. December 2004-2005

Sub-Investigator, Eyetech EOP I 0 II B. "A Phase II randomized. dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO." Primary Investigator: Sunil . Patel, M.D., Ph.D. August 2004-2005

Sub-Investigator, Anecortave Acetate Risk-Reduction Trial (AART) C-02-60. "Multicenter. double-masked, randomized, parallel groups cl in ical trial to demonstrate that Anccortave Acetate is safe and effective versus sham in arresting the progression of non-exudati ve AMD in patients who are at-risk for progres ing to exudative AMD." Primary investigator: Yu-Guang He, MD. Un iversity ofTexas Southwestern Medical Center, Dallas, Texas. January-July 2004

Sub-Investigator, Anecortave Acetate Posterior Juxtascleral lnjection Protocol Number C-0 1-99. "Multicenter clinica l trial to eva luate the safety and efficacy of Anecortave Acetate in maintaining vision in patients with wet AMD as compared to the effectiveness of treatment with Visudyne PDT. " Primary investigator: Yu-Guang He, MD. Univer ity ofTexas Southwestern Medical Center, Dallas, Texas. 2003.

Co-Investigator and author of "Multimodality Transpupi llary Thermotherapy and Radiotherapy of Choroidal Neovascular Membranes in Age-Related Macular Degeneration: A Phase I Safety Study.'' Clin ical study to examine the safety of laser thermotherapy and external beam irradiation in the treatment of choroidalneovascular membranes in age-related macular degeneration. Co-investigator: Dennis M. Marcus, MD. Medica l College of Georgia, Augusta, Georgia. July 2000-2002. Research Assistant. Examined the role of preoperative levels of alpha2-antiplasmin in identifying patients at increased risk for bleeding during different card iac surgical procedures. Primary Investigator: Charles Whitten, MD. Department of Anesthesiology, University of Texas Southwestern Medica l School, Dallas, Texas. 1995.

Research Assistant. Analyzed changes in card iac contractile function during hemorrhagic shock and attempted resuscitation. Primary investigator: Dan Meyer, MD. Department of Thoracic and Cardiovascular Surgery, University of Texas Southwestern Medical School, Dallas, Texas. 1992-1994.

PUBLICATIONS

Campochiaro PA, Brown OM, Awh CC, Lee SY, GrayS, Saroj N, Murahashi WY, Rubio RG. Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase Ill Study. Ophthalmology. 20 II: 118:2041-2049.

Mitchell KT, Lee. S.Y. Current Options for Retinal Detachment Repair. Focal Points: Clinical Modules for Ophthalmologists, Volume XXV Ill Num ber 9, Sep 2010.

Scott JU, lp MS, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonza lez VH, Singerman LJ , To lentino M;SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to Branch Retinal Vein Occlusion: SCORE tudy Report 6 Arch Ophthalmol. 2009 Sep; 127(9): I I 15-28

lp MS, Scott IU, Van Veldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcino lone with observation to treat vision loss associated with macular edema secondary to Central Retinal Vein Occlusion: SCORE Study Report 5 Arch Ophthalmol. 2009 Sep; 127 (9): I I 01-14

S.Y.Lee, Dyer 0 , Callanan D, Bochow T, Abraham P, Lambert HM, Schneiderman T, Potts SL, Walker TM. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40mglml) for visualization during pars plana vitrectomy. Retina 2009 29(1):38-45 PMI D 18827733

Domalpally A, Blodi SA, colt lu, lp M , Oden NL, Lauer AK, Van Veldhuisen PC, and SCORE Study Investigator Group. The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Optical Coherence Tomograms: Score Study Report 4 Arch Ophthalmol. 2009; 127 (I I): 1461-1467

Diabetic Retinopathy Clinical Research Network. (S.Y. Lee, Participating Clinical Investigator). A Randomized Trail Comparing lntravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema. Ophthalmology, 2008; 115: 1447-1459

S.Y. Lee, P. Jagannathan, A.O. Edwards. "Retinal Pigment Epithelial Rip Following lntravitreal Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration." Submitted for publication June, 2003.

D.M. Meyer, M.E. Jessen, R. Y. Cbao, C. Barak, S.Y. Lee. " Recovery of Right Ventricular Function after Severe Hemorrhagic Shock- Re u citation Using Extracorporeal Assisted Circulation." Shock, Supplement I :8, 1994.

D.M. Meyer, M.E. Jessen, R.Y. Chao, C. Barak, S.Y.Lee. "Effects ofExtracorporeal Assisted Circulation on Recovery from Shock.'' CirculatmyShock, Supplement 2: 10, 1993.

BOOK CHAPTER

W.C. Sheils, S.Y. Lee, D.M. Marcus. " Radiation Therapy for Age-Related Macular Degeneration." in Age-Related Macular Degenerctlion: Current Treatment Concepts, edited by W.E. Alberti, G. Richard, R.H. Sagerman. Pp. 189-198. New York: Springer-Verlag, 2000.

AB TRACT

D.Parver, S.Y. Lee, Y.-G. He and J.P. Me Culley. Evaluation of Vitreo-Retinal Procedures Combined with Cataract Extraction and Implantation of the AcrysofNatural Intraocular Lens. Invest Ophthalmol Vis Sci 200-1,-45: £-Abstract 331

Multimodality Transpupillary Thermotherapy and Radiotherapy of Choroidal Neovascular Membranes in Age-Related Macular Degeneration: A Phase I afety Study. Lee. S.Y., Sheils, W.C., Redd, J., Samy, C.N., Marcus, D.M. lnvesi.Ophthalmol. Vis.Sci. 2002; 43 (suppl): Abstract #4411

C. Whitten, P. Grei lich, D. Young, R. Ivy, S.Y. Lee, P. Allison. " Do Preoperative Levels of Alphar Antiplasmin Vary for Different Cardiac Surgical Procedures?" American Society of Anesthesiologists: 1997 Abslrac/s.

PRESENTATIONS

S.Y. Lee, B. Wall , S.B. Mcintosh, C.N. Samy, W.C. Sheils, D.M. Marcus. "Laser Photocoagulation With Adjuvant External Beam Irradiation Fo1· Non-Foveal Classic Choroidal Neovascular Membranes in Age Related Macular Degeneration." ARVO AnnuaJ Meeting, Fort Lauderdale, Florida, 200 I.

S.Y. Lee, W.C. Sheils, J. Redd, C.N. Samy, D. M. Marcus. " Multimodality Transpupi llary Thermotherapy and Radiotherapy of Choroidal Ncovascular Membranes in Age-Related Macular Degeneration: A Phase I Safety Study." ARVO Annual Meeting, Fort Lauderdale, Florida, 2002.

CERTIFJCATION

Diplomate of the American Board of Ophthalmology (Board certified May 2004)

Investigator Education for the Protection of Human Research Subjects with HIPPA Privacy Rule Component (June 28, 2004)

LICENSE

Texas, #K7796, 1999 to present

PROFESSIONAL ORGANIZATIONS

American Academy of OphtJ1almology Texas Ophthalmological Association American Society of Cataract and Refractive Surgery American Society of Retina Specialists

Revision date: January 20 12